$MRK News

Merck (MRK) Stock Sinks As Market Gains: Here's Why

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

FDA Approves Pembrolizumab Or Pembrolizumab And Berahyaluronidase Alfa-pmph Each With Enfortumab Vedotin-ejfv For Muscle Invasive Bladder Cancer

This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

Morgan Stanley Maintains Equal-Weight on Merck & Co, Raises Price Target to $113

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck (MRK) Gets New HIV Access Deal As Its Valuation Narrative Stays In Focus

Will New KEYTRUDA Breast and Bladder Cancer Approvals Redefine Merck’s (MRK) Post-Exclusivity Narrative?

MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?

RBC Capital Reiterates Outperform on Merck & Co, Maintains $142 Price Target

Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $150

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

Cantor Fitzgerald Reiterates Neutral on Merck & Co, Maintains $120 Price Target

Merck (MRK) Wins New KEYTRUDA Approvals As Tulisokibart Clears A Phase 3 Test

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Merck (MRK) Faces U.S. Security Probe Over China Clinical Trials

Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says

B of A Securities Maintains Buy on Merck & Co, Raises Price Target to $141

Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $155